Endovascular Stent Market Report: Trends, Forecast and Competitive Analysis to 2031

The global endovascular stent market is expected to grow with a CAGR of 8.5% from 2025 to 2031. The major drivers for this market are the increasing prevalence of cardiovascular diseases, the growing demand for minimally invasive procedures, and the rising adoption of advanced medical technologies.

The future of the global endovascular stent market looks promising with opportunities in the hospital & cardiovascular center and ambulatory surgical center markets.

• Within the product category, endovascular aneurysm repair stent is expected to witness the highest growth over the forecast period.
• Within the end use category, hospital & cardiovascular center is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Endovascular Stent Market

The endovascular stent market is now defined by a number of revolutionary emerging trends that are revolutionizing cardiovascular and peripheral vascular treatments. These trends indicate a coordinated endeavor to promote patient safety, enhance long-term results, and broaden stent technology applications outside the conventional uses. From bioresorbable materials to intelligent, networked devices, all these innovations are important in trying to understand the future direction of the industry. This section describes five of the most important emerging trends, and their implications for product innovation, clinical practice, and patient care.

• Bioresorbable Scaffolds/Stents: This trend encompasses stents that are intended to give temporary mechanical support and deliver medication, and eventually dissolve and be absorbed by the body without any permanent implant. This would restore the natural function and flexibility of the vessel. The evolution of BRS resolves issues with long-term issues associated with metallic stents, such as chronic inflammation, late thrombosis of the stent, and the need for re-intervention in the future. The effect is a paradigm shift towards temporary implants, hopefully leading to healthier vessels and possibly eliminating the necessity for prolonged antiplatelet therapy in the future.
• Drug-Coated Balloons and Drug-Eluting Stents Evolution: The market is witnessing ongoing evolution in drug-eluting technologies. This encompasses next-generation DES with enhanced polymer biocompatibility, reduced strut thickness, and more refined drug release profiles, with the goal of lowering restenosis rates without diminishing adverse events. In parallel, drug-coated balloons (DCBs) are increasingly being used, especially to treat in-stent restenosis or smaller arteries, as they provide anti-proliferative medication without depositing a permanent implant. The effect is enhanced efficacy, fewer side effects, and a broader spectrum of treatment for different vascular lesions.
• Personalized and Patient-Specific Stents: It is an upcoming trend that aims to customize stent configuration and characteristics according to the patient's specific anatomy and disease morphology. With the use of sophisticated imaging and computational modeling, stents may be designed for custom fit, radial strength, and drug elution based on particular lesions or vessel shapes. Although still in its infancy, 3D printing and other advanced manufacturing are technologies that could make this possible. The effect is a transition towards precision medicine in endovascular therapy, allowing for potentially improved procedural success rates, fewer complications, and improved long-term results by matching individual patient requirements.
• Improved Imaging and Navigation Integration: Combining improved imaging modalities (such as IVUS and OCT) and navigation systems (with AI-driven guidance systems) during stent placement is a key trend. These tools deliver real-time high-resolution images of the vessel and stent positioning with improved accuracy for deployment, and for maximizing outcomes. The effect is enhanced procedural precision, lower radiation dose exposure to patients and clinicians, and more accurate stent-vessel interaction comprehension, resulting in improved immediate and long-term outcomes and fewer complications.
• Greater Emphasis on Peripheral Artery Disease & Complex Aortic Procedures: Although coronary stents have taken center stage in the past, there is an increasing inclination toward specialized endovascular treatments for peripheral artery disease (PAD) and complex aortic diseases (e.g., fenestrated/branched EVAR, dissection repair). These include stents and stent grafts tailored to the anatomy of particular vessels, tortuosity, and disease specifics of those locations. The effect is a widening of the addressable market beyond coronary intervention with effective minimally invasive therapy for a wider variety of vascular disease and enhancing quality of life in a greater population of patients.

These new trends are all coming together to restructure the endovascular stent market by fueling a sustained search for better patient outcomes and increased clinical utility. The future of permanent implantation is promised away with bioresorbable scaffolds, while drug delivery system improvements and customized stents provide more targeted and effective interventions. Advanced imaging and navigation technologies are enhancing procedural precision, and the growing emphasis on PAD and complicated aortic interventions is expanding the market's scope. This transition represents a market that is more innovative, patient-driven, and able to treat a broader range of vascular disease with minimally invasive treatments.

Recent Developments in the Endovascular Stent Market

The endovascular stent market has seen a spate of recent key developments driven by continued medical device technology innovation and growing global burden of cardiovascular and peripheral vascular illnesses. These new developments are intended to provide better treatment outcomes, better patient safety, and greater potential for minimally invasive endovascular intervention. From innovative stent designs to advanced delivery systems, these technologies are constantly advancing the limits of interventional cardiology and vascular surgery. Here, this section will present five of the most important recent developments, with their significant contributions toward enhancing patient care.

• Introduction of Next-Generation Drug-Eluting Stents: One of the most important recent developments is the ongoing improvement and release of next-generation drug-eluting stents. These more recent DES have thinner struts, more biocompatible polymers, and better optimized drug release kinetics, all designed to minimize inflammation and enable healing to occur more rapidly while being equally effective at precluding restenosis. Such examples include bioabsorbable polymer or polymer-free stents. The effect is enhanced long-term outcomes, minimized late stent thrombosis rates, and an expanded number of patients who can derive benefit from these next-generation coronary and peripheral interventions.
• Advances in Endovascular Aneurysm Repair Stent Grafts: In the last few years, there have been remarkable advances in stent grafts for Endovascular Aneurysm Repair (EVAR) of abdominal and thoracic aortic aneurysms. Among them are the creation of fenestrated and branched stent grafts, with which the important branch vessels (such as renal or visceral arteries) can be preserved during the repair of aneurysms, thereby more patients becoming candidates for this endovascular procedure. The effect is a significant increase in treatable anatomies, decreased invasiveness relative to open surgery, diminished perioperative risks, and quicker patient recovery times for complex aortic diseases.
• Increased Utilization of Bioresorbable Vascular Scaffolds in Clinical Studies: Though there were early market difficulties, there has been a revived interest in bioresorbable vascular scaffolds (BVS). Latest advances include ongoing clinical tests and studies of novel BVS material, design that overcomes the earlier shortfalls in mechanical properties and degradation rates. The goal is the development of scaffolds for temporary support and drug delivery followed by complete resorption to restore normal vessel function. The effect, if realized, would transform treatment by providing a permanent solution to vessel blockage without the permanent metallic implant.
• Stent Development for Multicomplex Peripheral Artery Disease: Advanced developments consist of dedicated stents and stent grafts that tackle the specific issues of complex peripheral artery disease, especially for highly calcified or long, diffuse SFA and below-the-knee artery lesions. New developments encompass braided stents, covered stents, and drug-eluting stents customized for peripheral arteries, with enhanced flexibility and fracture resistance. The effect is better patency rates in difficult peripheral vessels, fewer limb amputations, and better quality of life for patients with advanced PAD.
• Miniaturization and Better Deliverability of Stents: A key recent advance across the board is ongoing miniaturization of stent profiles and improvements in delivery system design. This facilitates easier delivery through tortuous and calcified arteries, minimizing procedural complexity and better access to formerly untreatable lesions. Smaller catheter diameters and more flexible delivery systems enable less invasive access points and minimize vascular complications. The effect is safer and more convenient procedures, especially for elderly or high-risk patients, further broadening the use of endovascular interventions.

These new advances are having a deeply impacting influence on the endovascular stent market by encouraging innovation towards safer, more effective, and more widely applicable solutions. Development of next-generation DES and newer EVAR stent grafts improves patient outcomes considerably and increases treatable conditions. Revitalized interest in bioresorbable scaffolds promises an era of temporary implants, while dedicated stents for complex PAD provide promise for tough-to-treat lesions. Additionally, miniaturization and enhanced deliverability make interventions safer and more available. Taken together, these developments make endovascular stents the pillar of contemporary interventional medicine, providing superior alternatives to conventional surgery.

Strategic Growth Opportunities in the Endovascular Stent Market

The endovascular stent market offers compelling strategic growth opportunities across key applications due to the rising global burden of cardiovascular and peripheral vascular diseases and the ongoing development of interventional technologies. With healthcare systems worldwide emphasizing minimally invasive therapies, the customization of stent solutions to particular disease states and anatomical complexities becomes essential to fuel market growth. Identifying and capitalizing on these application-driven opportunities enables healthcare providers and manufacturers to meet unmet patient needs and create solid market positions. This section will discuss five critical growth opportunities based on application, demonstrating their potential to make a significant difference in market size.

• Coronary Artery Disease Interventions: With all the maturity in this area, the coronary artery disease (CAD) segment is still the biggest and most stable growth opportunity. Strategic expansion lies in the creation of next-generation drug-eluting stents with enhanced long-term patency, lower inflammation, and improved deliverability for tough lesions (i.e., bifurcations, chronic total occlusions). Personalized medicine solutions also represent opportunity, leveraging individual patient features to optimize stent choice and deployment. Emphasis on clinical data, cost containment, and real-world results will perpetuate market leadership and patient value in this high-stakes application.
• Peripheral Artery Disease Treatments: The PAD segment is a high-growth opportunity because of the increasing global incidence of PAD, particularly in the diabetic and aged populations. Strategic expansion includes creating specialized stents in different peripheral arteries (e.g., superficial femoral artery, popliteal, below-the-knee arteries) with superior flexibility, fracture resistance, and long-term patency in complex anatomies. Drug-coated balloon and drug-eluting stent innovation tailored for peripheral use will stimulate market growth with long-lasting solutions for limb salvage and enhanced patient mobility.
• Abdominal Aortic Aneurysm and Thoracic Aortic Aneurysm (TAA) Repair: The endovascular repair of abdominal aortic aneurysms (AAA) and thoracic aortic aneurysms (TAA) market presents high premium growth potential. Strategic growth is driven by the development of sophisticated stent grafts, such as fenestrated and branched stent grafts, that increase the population eligible for minimally invasive repair to complex aortic anatomy patients who once needed open repair. Delivery system innovation, device conformability, and durability over time will be important to gain market share and better outcomes in this high-risk patient population.
• Neurovascular Procedures: The neurovascular segment, albeit smaller, is a high-growth opportunity in the making. This encompasses specialized stents and flow diverters for intracranial aneurysm treatment, stent retrievers and intracranial stents for acute ischemic stroke. Strategic expansion requires heavy R&D investment in highly accurate, miniaturized devices having superior navigability and safety profiles for sensitive brain vasculature. The rising incidence of stroke and advancements in neuro-interventional strategies will propel strong future demand.
• Renal Artery Stenosis and Other Visceral Artery Interventions: Growth is possible in the treatment of renal artery stenosis and other visceral artery ailments, sometimes concomitant with hypertension or chronic mesenteric ischemia. Strategic expansion is seen in the creation of stents tailored for the renal and mesenteric arteries, given their specific anatomy, tortuosity, and disease course. Emphasis on long-term patency and lower rates of restenosis will be critical. Though a niche market, the chronic condition of these diseases and the potential for meaningful clinical improvement offer it value as a target area for special stent development and market entry.

These strategic growth prospects are having a deep impact upon the endovascular stent market by segmenting and diversifying its interest to cover a greater variety of vascular ailments. Although coronary interventions continue to be the core, the strong growth in peripheral artery disease, advanced aortic repairs, and neurovascular uses is reshaping market trends. The new prospects in renal and other visceral artery interventions represent the market's ongoing specialization. By focusing strategically on these varied application-based growth opportunities, the endovascular stent market can experience sustained growth, greater market penetration, and continue to enhance patient outcomes throughout the range of vascular diseases.

Endovascular Stent Market Drivers and Challenges

The endovascular stent market is characterized by a vibrant relationship between key drivers and challenges such as diverse technological, economic, and regulatory factors. Key drivers like the rising global burden of cardiovascular diseases and improved stent technology are driving market growth by enhancing the need for minimally invasive procedures. Conversely, significant challenges, including high procedural costs, regulatory complexities, and the risk of in-stent restenosis, can impede growth and necessitate strategic adjustments from market participants. This analysis will delve into the primary forces advancing the endovascular stent market and the key obstacles that demand careful navigation, ultimately synthesizing their overall impact on the industry's trajectory.

The factors responsible for driving the endovascular stent market include:

• Rising Prevalence of Cardiovascular Diseases: The mounting worldwide prevalence and incidence of cardiovascular conditions, including peripheral artery disease, coronary artery disease, and aneurysms, are the strongest drivers. Lifestyle determinants like obesity and diabetes, smoking, sedentary living, and unhealthy eating habits drive this burden. With more people developing these conditions, naturally the need for efficient treatment methods such as endovascular stenting increases, resulting in an ongoing and widening patient population for the market.
• Increasing Demand for Minimally Invasive Procedures: There is an established and growing worldwide desire among patients and medical practitioners alike for minimal invasion through surgical operations compared to the use of the traditional open procedure. Endovascular stenting presents advantages in the form of less invasive wounds, less pain, shorter hospitalization periods, quicker recovery times, and fewer complications risks. This patient-focusing transition heavily influences the use of stents since they perfectly capture current healthcare patterns of using fewer invasive and more effective treatment approaches.
• Technological Innovation and Product Development: Ongoing innovation in stent technology is the key driver. These involve the creation of the next generation of drug-eluting stents (DES) with enhanced drug delivery and biocompatibility, and the introduction of bioresorbable scaffolds (BRS) that can potentially replace permanent implants. Stent design innovation (e.g., reduced struts, improved flexibility), materials (e.g., new alloys, polymers), and delivery systems (e.g., improved navigability) continuously enhance clinical outcomes and extend the indications for stenting, thus fueling market growth.
• Aging Global Population: The world population is aging quickly, and elderly people are disproportionately vulnerable to peripheral vascular and cardiovascular illness. With the growth of the geriatric population, so does the incidence of vascular pathologies that need to be treated with endovascular stents. This population change is a demographic tailwind for the endovascular stent market, guaranteeing an increasing patient population that needs to be treated for age-related vascular disease.
• Favorable Reimbursement Policies and Healthcare Infrastructure Development: Generous reimbursement policies in most developed nations that offset the expense of stent procedures enhance their affordability and attractiveness to patients. At the same time, constant improvement and upgrading of healthcare facilities, especially in emerging nations, are raising access levels to specialized cardiovascular treatments, including interventional cardiology and vascular surgery. This enhanced access and affordability directly lead to greater stent adoption rates.

Challenges in the endovascular stent market are:

• High Cost of Stent Procedures and Devices: One major challenge is the comparatively high expense of endovascular stent procedures, which encompasses the cost of the stent devices themselves, the costs of the specialized equipment, as well as the fees of professionals. This can restrict access to therapy, especially in developing nations or in uninsured/underinsured patients. It also creates pressures on healthcare budgets and reimbursement mechanisms, and this can contribute to controversy over pricing and value, which can limit market growth.
• Risk of In-Stent Restenosis and Device Thrombosis: In spite of progress, the threat of in-stent restenosis (ISR) - re-narrowing of the stented vessel - and, less frequently, stent thrombosis, continues to be an ongoing clinical dilemma. Although DES have lowered ISR dramatically over bare-metal stents, the problems still recur and may need to be treated with repeated procedures. These hazards keep clinicians and patients concerned and dampen the enthusiasm for stenting procedures, compelling ongoing research for even more effective and safer alternatives.
• Comprehensive Regulatory Approvals and Clinical Evidence Standards: The endovascular stent market is subject to demanding and frequently protracted regulatory clearance procedures, especially for new technologies such as bioresorbable scaffolds or emerging drug-eluting platforms. Showing long-term safety and effectiveness through extensive and expensive clinical trials is required. Such strict requirements, which differ between nations, prolong the time and money needed by manufacturers, hindering the commercialization of products and even restricting the expedited introduction of new technology.

The endovascular stent market exists in a condition of dynamic tension, propelled by the increasing demand for cardiovascular interventions and incredible technology advances but bogged down by daunting clinical and economic barriers. The increasing incidence of CVDs, demand for less invasive treatments, and an aging population are strong market drivers. Nevertheless, the procedure costs, the long-standing issue of in-stent restenosis, and intricate regulatory environments pose significant barriers. For long-term growth, the market needs to focus on cost-effectiveness, further minimize long-term complications, and traverse complex regulatory channels, so that innovative, life-saving stent technologies prove effective and accessible to all.

List of Endovascular Stent Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies endovascular stent companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.

Some of the endovascular stent companies profiled in this report include:

• Abbott Laboratories
• Boston Scientific
• Medtronic
• Cardinal Health
• B. Braun Melsungen
• Biotronik
• Cook Medical
• Terumo
• Microport Scientific
• Meril Life Sciences

Endovascular Stent Market by Segment

The study includes a forecast for the global endovascular stent market by product, application, end use, and region.

Product [Value from 2019 to 2031]:

• Endovascular Aneurysm Repair Stents
• Fenestrated Evar
• Aortic Stents
• Thoracic Aortic Aneurysm Graft Stents

Application [Value from 2019 to 2031]:

• Thoracic Aortic Aneurysm
• Abdominal Aortic Aneurysm
• Others

Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country-Wise Outlook for the Endovascular Stent Market

The endovascular stent market is rapidly evolving on the back of the rising worldwide incidence of cardiovascular diseases and greater demand for minimally invasive surgical procedures. Advances focus on enhancing patient outcomes, lowering recovery times, and increasing the use of stent technology. Developments include material science, drug delivery systems, and device design, handling complex anatomies and long-term patency. Grasping these regional developments is important for understanding the changing landscape of the market and growth patterns going forward in key global healthcare systems.

• United States: The United States endovascular stent market is a prime center of innovation, with high research and development investment. Emerging trends center on sophisticated drug-eluting stents (DES) to achieve better long-term patency and lower rates of restenosis, and commercialization of bioresorbable stents. Also highlighted is a strong focus on stent grafts for endovascular aneurysm repair (EVAR) and thoracic aortic aneurysm (TAA) repair, providing alternatives to open surgery that are less invasive. Favorable reimbursement policy and high rates of cardiovascular diseases continue to propel market growth and technology uptake.
• China: China's endovascular stent market is growing at a fast pace, driven by its sizeable and ageing population, rising rates of cardiovascular diseases, and improving healthcare infrastructure. Recent trends have involved substantial domestic manufacturing capacity growth and emphasis on creating more affordable yet efficient stents to address a huge patient base. Though drug-eluting stents currently lead the market, investors and interest are on the rise for bioresorbable and niche stents. Government incentives for domestic innovation and increased healthcare access are major drivers for market growth.
• Germany: Germany's endovascular stent market is dominated by a demand for high-quality, clinically validated, and sophisticated stent technologies. Recent trends are focused on next-generation drug-eluting stents with better biocompatibility and targeted drug release. There is also high adoption of peripheral vascular stents and stent grafts in the treatment of complex aortic diseases. The market enjoys a well-developed healthcare system, high spending on healthcare, and an emphasis on clinical evidence and patient safety, fueling demand for high-quality and innovative solutions.
• India: India's endovascular stent market is experiencing high growth due to an expanding burden of cardiovascular diseases, enhanced access to healthcare, and rising affordability of medical treatment. Recent trends include entry by competitive local manufacturers, resulting in more affordable pricing for stents. Demand for drug-eluting stents is very high, with an increasing trend for sophisticated designs and materials. Government policies to control stent prices and encourage domestic production are affecting market dynamics, balancing patient affordability with innovation.
• Japan: The endovascular stent market in Japan is very advanced, focusing on precision, long-term results, and sophisticated technologies. Recent advancements involve the ongoing optimization of drug-eluting stents for peak drug release and minimal inflammation, together with intense research on bioresorbable scaffolds. Japan also has a high emphasis on dedicated stents for peripheral artery disease and cerebral aneurysms, in view of its aging population and high medical care standards. Supportive reimbursement and a keen interest in clinical data underpin the take-up of advanced stent technologies.

Features of this Global Endovascular Stent Market Report

• Market Size Estimates: Endovascular stent market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Endovascular stent market size by product, application, end use, and region in terms of value ($B).
• Regional Analysis: Endovascular stent market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different products, applications, end uses, and regions for the endovascular stent market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the endovascular stent market.
• Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

This report answers the following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the endovascular stent market by product (endovascular aneurysm repair stents, fenestrated evar, aortic stents, and thoracic aortic aneurysm graft stents), application (thoracic aortic aneurysm, abdominal aortic aneurysm, and others), end use (hospitals & cardiovascular centers, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

This product will be delivered within 1-3 business days.